A5101636640- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cardiac Valve Diseases and Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Tracheal and airway disorders
- Renal cell carcinoma treatment
- Dementia and Cognitive Impairment Research
- Congenital Heart Disease Studies
- Health disparities and outcomes
- Pulmonary Hypertension Research and Treatments
- Neuroscience of respiration and sleep
- Cancer Cells and Metastasis
- Aortic Disease and Treatment Approaches
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Obstructive Sleep Apnea Research
- Lung Cancer Research Studies
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- High Altitude and Hypoxia
- Immune Cell Function and Interaction
Tianjin Medical University General Hospital
2013-2025
Guangxi Medical University
2023-2025
Peking University
2019-2025
Peking University Cancer Hospital
2019-2025
Sichuan University
2021-2025
Tengzhou Central People's Hospital
2024
Fourth Affiliated Hospital of Guangxi Medical University
2024
West China Hospital of Sichuan University
2023
Jilin University
2021-2023
West China Medical Center of Sichuan University
2023
Background Although anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma.We hypothesize that there are discrepancies of survival, recurrence pattern and toxicity to PD-1 between different ethnicities melanoma subtypes. Objective/methodsWe performed multicenter cohort study incorporating 6 independent institutions in Australia, China, Japan, US.The primary outcomes were RFS OS.Secondary disease patterns toxicities. ResultsIn total 534...
Background This study aimed to investigate and analyze the current status of oral disease treatment among older adult in Guangxi Zhuang Autonomous Region, while also assessing continuing medical education (CME) needs dental institution personnel regarding diseases this population. Methods Convenience sampling was used adults assess CME population across various health institutions Guangxi. Results A total 754 valid questionnaires were collected, which 70.3% from non-public institutions....
<title>Abstract</title> Central airway obstruction can be secondary to extrinsic compression from surrounding structures, direct extension an adjacent tumor, metastatic disease and, less commonly primary intrinsic endobronchial malignancies.To our knowledge, nearly few reports of isolated central lesion by lymphoma without extrathoracic or extra-nodal manifestation have been published date. This is the first case about malignant trachea caused B-cell involvement main stem bronchi, lobar...
Purpose Despite the wealth of data on role chronic disease comorbidity in shaping cognitive dysfunction older adults, a comprehensive view this dynamic interplay remains frontier. This study will reveal intricate interactions between number diseases and function elderly, based perspective patients with multiple diseases. Methods Our was from 2023 China Psychological Care for Elderly Action Survey, SPSS 26.0 (IBM Corp., Armonk, NY, United States) software package used mediation model...
This study aims to explore the clinical characteristics and prognosis of patients with melanoma (MM), which are composed mainly acral mucosal MM accompanied by multiple primary tumors. A total 87 diagnosed single malignant tumors were included. Nonmelanoma malignancy tumor type, genetic testing, survival data collected. Pearson's chi-square test, Fisher's exact log-rank univariate multivariate Cox's regression analysis applied. The most common nonmelanoma malignancies in all involved...
Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma the multi-centre phase II study. This report updates 3-year survival outcomes and multi-omics analysis to identify potential response biomarkers.
e21571 Background: Novel individualized neoantigen vaccine showed durable survival benefit when combined with anti-PD-1(aPD-1) vs aPD-1 alone. Dendritic cell cytokine-induced killer (DC-CIK) was classic cellular antitumor therapy. However, whether DC -CIK prolong in resected melanoma remains unknown. We conducted this single center, retrospective study designed to compare the efficacy of relapse free (RFS) and overall (OS) DC+ interferon (IFN), IFN alone, alone stage III acral/cutaneous...
9508 Background: Chemotherapy (temozolomide plus cisplatin) has been demonstrated to be a better adjuvant regimen compared high-dose interferon alpha-2b in resected Mucosal Melanoma (MuM) the pre-immunotherapy era. Yet present immunotherapy era, PD-1 inhibitor was recommended as standard therapy for Melanoma. No trial comparing chemotherapy with MuM had reported. we conducted this study determine efficacies of versus MuM. Methods: All patients (pts) received 200 mg/m 2 /day orally on days 1...
Cancer stem cells (CSCs) from various cancers are able to transdifferentiate into endothelial and further form functional blood vessels, indicating another possible resistance mechanism antiangiogenic agents. However, it remains unclear whether CSCs hepatocellular carcinoma have the ability differentiate cells, thus resulting in therapy targeting VEGF. Reactive oxygen species (ROS) involved self-renewal differentiation of CSCs, yet, their role has been poorly understood. In this study, we...
9580 Background: Combination therapy of anti-PD1 agent with VEGFR inhibitor is a promising therapeutic approach in unresectable or metastatic mucosal melanoma. We conducted this study evaluating neoadjuvant lenvatinib and pembrolizumab pts resectable Methods: This was single-arm, open-label, single-center, phase 2 from Sep 2021. Eligible were adults (18-75 yr) histologically confirmed, Pts received 20mg qd 200mg q3w for cycles, followed by surgery. Pembrolizumab (200mg q3w) continued post...
Objective To investigate the prevalence of hypertension and circadian blood pressure (BP) variations in patients with obstructive sleep apnoea–hypopnoea syndrome (OSAHS). Methods Patients referred to a clinic underwent polysomnography measurement BP at four time points. They were classified into groups (control, mild, moderate or severe apnoea) using index (AHI). Circadian variation was assessed night-time daytime mean ( R N/D ) morning evening M/E ratios. Results Hypertension significantly...
<h3>Objectives</h3> To examine the efficacy of intratracheal dexmedetomidine (Dex) injection for prevention laryngeal response on emergence from general anaesthesia following gynaecological laparoscopic surgery. <h3>Design</h3> Prospective, randomised, double-blinded, controlled trial. <h3>Setting</h3> A hospital, Guangdong Province, China. <h3>Participants</h3> All patients who underwent elective surgery, aged 18–60 years old, 40–80 kg in weight, American Society Anesthesiologists class...
Pharmacognosy Magazine,2014,10,37s,s153-s158.DOI:10.4103/0973-1296.127367Published:February 2014Type:Original ArticleAuthors:Chunyuan Li, Bing Gong, Daniel G Cox, Caili Jinhua Wang, and Weijia Ding Author(s) affiliations:Chunyuan Li1, Gong1, Cox2, Li3, Wang1, Ding1 1 Institute of Biomaterial, College Science, South China Agricultural University, Guangzhou, 2 Department Research Pharmaceutical Sciences, School Pharmacy, the University Mississippi, Mississippi USA 3 Xinyang Branch, Henan...
The proliferation marker Ki67 is associated with the progression and prognosis of melanoma. However, its prognostic impact on acral melanoma (AM) remains unclear.A total 314 AM patients were enrolled from a cohort 5758 at Peking University Cancer Hospital between 2006 2018. divided into high- low-expressing groups using cut-off value 30%. associations clinicopathologic characteristics as well survival analyzed. Cox proportional regression analysis was used to establish nomogram predict...
To investigate the association of 3- and 6-month BCR-ABL transcript levels on international scale (BCR-ABL) other factors with deep molecular response (DMR) achievement in chronic myeloid leukemia (CML)-chronic phase (CP) patients receiving tyrosine kinase inhibitor (TKI) therapy.We retrospectively analyzed clinical data 206 enrolled our hospital between January 2010 July 2018. These were initially diagnosed CML-CP received imatinib or nilotinib therapy. Early (EMR) was assessed based (IS:...
10040 Background: Vorolanib (CM082) is a multi-target tyrosine kinase inhibitor including VEGF, PDGF, c-kit, and Flt-3. Toripalimab (JS001) humanized IgG4 mAb against programmed death-1 (PD-1) with clinical activity in metastasis melanoma but not its mucosal subtype. In this phase II study (NCT03602547), we investigated the safety efficacy of CM082 combination JS001 patients (pts) advanced melanoma. Methods: The enrolled pts from 18 to 75 years-old histologically confirmed metastatic...
Adjuvant chemotherapy (ACT) can improve prognosis for stages II-IIIA patients with non-small-cell lung cancer (NSCLC), but its implication in stage I is still an intractable puzzle. This study aims to seek ACT candidates IB NSCLC and establish a nomogram predict overall survival (OS) of specific patient clinician's decision.We performed retrospective on 16,765 (ACT group: n = 2,187; non-ACT 14,578) from the Surveillance, Epidemiology, End Results (SEER) database. Overall was assessed two...
Background: The best response and survival outcomes between advanced melanoma patients treated with the anti-PD-1 monotherapy vary greatly, rendering a risk model in need to optimally stratify based on their likelihood benefit from said treatment. Methods: We performed an ad hoc analysis of 89 two prospective clinical trials at Peking University Cancer Hospital April 2016 May 2018. Clinicodemographical characteristics, baseline early-on-treatment (median 0.6 months after initiation) routine...
9514 Background: Combination therapy of anti-PD1 agent with VEGFR inhibitor is a promising therapeutic approach in unresectable or metastatic mucosal melanoma. We conducted this study evaluating neoadjuvant lenvatinib and pembrolizumab pts resectable Methods: This was single-arm, open-label, single-center, ongoing phase 2 from Sep 2021. Eligible were adults (18-75 yr) histologically confirmed, Pts received 20mg qd 200mg q3w for cycles, followed by surgery. Pembrolizumab (200mg q3w) continued...